Health Care·Biotechnology·$14.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.18 | N/A | -35.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.18 | N/A | -35.17% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about current financial performance. They highlighted the need for strategic adjustments moving forward.
Management acknowledged challenges in achieving profitability.
They emphasized ongoing efforts to streamline operations.
BridgeBio Pharma's earnings report indicates ongoing struggles, particularly with EPS significantly missing expectations. The stock reacted negatively, dropping 6.33%, reflecting investor concerns about the company's financial health and lack of guidance. The absence of revenue figures further complicates the outlook for the company.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUNCOR ENERGY INC NE
May 3, 2021